Informatie:
Fout:
ID
18588
Beschrijving
A Randomized, Open-Label Study to Compare the Efficacy and Safety of AT1001 and Enzyme Replacement Therapy (ERT) in Patients With Fabry Disease and AT1001-Responsive GLA Mutations, Who Were Previously Treated With ERT Open Label Extension
Trefwoorden
Versies (2)
- 02-11-16 02-11-16 -
- 11-11-16 11-11-16 -
Geüploaded op
11 november 2016
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Open Label Extension Galafold (migalastat) AT1001-012 NCT01218659
Open Label Extension Galafold (migalastat) AT1001-012 NCT01218659
Similar models
Open Label Extension Galafold (migalastat) AT1001-012 NCT01218659
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Date of visit
Item
Date of visit
date
C1320303 (UMLS CUI [1])
Item
Will the subject continue into Open Label Extension?
integer
C3640652 (UMLS CUI [1])
CL Item
Yes, the subject successfully completed Visit 9/Month 18 and will continue into open label extension. Please proceed to Visit 10/Month 24. (1)
CL Item
No, the subject successfully completed Visit 9/Month 18 but will not continue into open label extension. Please ensure subject completes Visit 14/Month 19 or 31. (2)
CL Item
No, the subject terminated and did not complete Visit 9/Month 18. Please ensure subject completes Visit 14/Month 19 or 31. (3)